E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Hagop M. Kantarjian,Stefan Faderl,Guillermo Garcia-Manero,Selina M. Luger,Parameswaran Venugopal,Lori J. Maness,Meir Wetzler,Steven Coutre,Wendy Stock,David F. Claxton,Stuart L. Goldberg,Martha Arellano,Stephen A. Strickland,Karen Seiter,Gary J. Schiller,Elias Jabbour,Judy Chiao,William Plunkett +17 more
TL;DR: The efficacy and toxicity of sapacitabine, a novel oral cytosine nucleoside analogue, in elderly patients with AML seems active and tolerable, and the 400 mg dose schedule had the best efficacy profile.
Journal ArticleDOI
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Elias Jabbour,Koji Sasaki,Farhad Ravandi,Nicholas J. Short,Guillermo Garcia-Manero,Naval Daver,Tapan M. Kadia,Marina Konopleva,Nitin Jain,Jorge E. Cortes,Ghayas C. Issa,Jovitta Jacob,Monica Kwari,Philip A. Thompson,Rebecca Garris,Naveen Pemmaraju,Musa Yilmaz,Susan O'Brien,Hagop M. Kantarjian +18 more
TL;DR: The objective of the current analysis was to compare the outcome of patients who received a combination of inotuzumab ozogamicin plus low‐intensity chemotherapy (mini–hyperfractionated cyclophosphamide, vincristine, and dexamethasone [mini‐HCVD]) with or without blinatumomab.
Journal ArticleDOI
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Guillaume Richard-Carpentier,Elias Jabbour,Nicholas J. Short,Caitlin R. Rausch,Jonathan M. Savoy,Prithviraj Bose,Musa Yilmaz,Nitin Jain,Gautam Borthakur,Maro Ohanian,Yesid Alvarado,Michael Rytting,Partow Kebriaei,Marina Konopleva,Hagop M. Kantarjian,Farhad Ravandi +15 more
TL;DR: Combination therapy with venetoclax showed promising clinical efficacy in R/R T-ALL, and further studies are warranted to evaluate the clinical benefit of BCL2 inhibitors in T-all.
Journal ArticleDOI
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Preetesh Jain,Hagop M. Kantarjian,Mona Lisa Alattar,Mona Lisa Alattar,Elias Jabbour,Koji Sasaki,Graciela M. Nogueras González,Sara Dellasala,Sherry Pierce,Srdan Verstovsek,William G. Wierda,Gautam Borthakur,Farhad Ravandi,Susan O'Brien,Jorge E. Cortes +14 more
TL;DR: Treatment with imatinib 800 mg or the second-generation TKIs dasatinib or nilotinib resulted in superior and deeper responses than did standard-dose imatinIB, which were maintained after 5 years of follow-up, although more patients discontinued therapy.
Journal ArticleDOI
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
TL;DR: Although molecular monitoring has a clear role in assessing residual disease and determining the risk of disease progression in patients with CML, the importance of cytogenetic monitoring should not be ignored.